WPD Pharmaceuticals Inc. (CSE:WBIO)
Canada · Delayed Price · Currency is CAD | Market Cap | 324.76K -93.6% |
| Revenue (ttm) | n/a |
| Net Income | -6.71K |
| EPS | -0.00 |
| Shares Out | 4.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,000 |
| Open | 0.0700 |
| Previous Close | 0.0700 |
| Day's Range | 0.0700 - 0.0700 |
| 52-Week Range | 0.0700 - 1.1250 |
| Beta | -0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 11, 2026 |
About WPD Pharmaceuticals
WPD Pharmaceuticals Inc. does not have any significant operations. Previously, it was engaged in the research and development of medicinal products in the fields of oncology. The company is headquartered in Vancouver, Canada. [Read more]
Financial Performance
Financial StatementsNews
CSE Bulletin: Reinstatement - WPD Pharmaceuticals Inc. (WBIO)
Toronto, Ontario--(Newsfile Corp. - le 20 décembre/December 2024) - Effective immediately, WPD Pharmaceuticals Inc. will be reinstated for trading. The Company has rectified the situation that gave ri...
WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company announces that th...
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce t...
WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project
Expert research team aiming to optimize the effects of radiotherapy of brain tumors Expert research team aiming to optimize the effects of radiotherapy of brain tumors
WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company's board of directors (the “Board”) h...
WPD Pharmaceuticals Announces Appointment of New Director
VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that the Company appointed Mr. Romuald ...
WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during th...
WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech
VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended and...
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML
VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce ...
WPD Pharmaceuticals Announces AGSM Results
VANCOUVER, British Columbia, Oct. 01, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces the results o...
WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland
VANCOUVER, British Columbia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces that it will...
WPD Pharmaceuticals' Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce ...